文献速递会诊联络精神医学心境障碍精神分裂症与精神病性障碍

精神障碍患者糖尿病治疗与监测差异:系统综述与荟萃分析

Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2026-01-05

BACKGROUND: People with mental disorders have an increased risk of diabetes, yet conflicting evidence exists regarding the quality of diabetes care they receive.…

要点

  • HbA1c检测、视网膜筛查、血脂检测、足部检查和肾脏检查的几率均显著降低。

核心结论

  • 精神障碍与接受充分糖尿病监测和GLP-1受体激动剂治疗的几率降低相关。
  • 解决这些差异可能有助于降低精神障碍相关的超额死亡率。

研究设计与样本

  • 系统综述与随机效应荟萃分析,检索Scopus、Embase、MEDLINE和PsycINFO至2025年2月8日。
  • 采用纽卡斯尔-渥太华量表(NOS)评估研究质量,大多数研究为高质量。

主要发现

  • 未发现发表偏倚证据。

关键数值与推荐

  • 主要结局为糖尿病质量护理的二元复合指标,即接受任何糖尿病监测和治疗(包括尿白蛋白-肌酐比值检测、HbA1c检测、血压测量、足部监测、血清肌酐检测、血清胆固醇检测、BMI记录、吸烟状态记录、视网膜监测)的人群百分比。
  • 次要结局为与九项NICE糖尿病监测指标匹配的研究特异性糖尿病质量护理个体指标及特定糖尿病干预和抗糖尿病药物。

临床怎么用

  • 临床应关注合并精神障碍的糖尿病患者,主动筛查并确保其接受推荐的糖尿病监测和个体化治疗。
  • 对合并精神障碍者,需注意GLP-1受体激动剂使用不足和胰岛素使用较多的情况,优化降糖方案。
  • 精神心理科医生应与内分泌科协作,减少糖尿病监测和治疗中的差异。

局限性

  • 研究间存在异质性,部分指标合并研究数量较少(如吸烟状态仅2项、GLP-1受体激动剂仅2项)。
  • 精神障碍诊断标准在40项研究中基于ICD-9或ICD-10,其余研究定义可能不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with mental disorders have an increased risk of diabetes, yet conflicting evidence exists regarding the quality of diabetes care they receive. To address this evidence gap, we conducted a systematic review and meta-analysis to assess and compare diabetes quality of care in people with diabetes with mental disorders versus people with diabetes without mental disorders. METHODS: In this systematic review and random-effects meta-analysis, we searched Scopus, Embase, MEDLINE, and PsycINFO for cohort and case-control studies published between database inception and Feb 8, 2025. We estimated summary odds ratios (ORs) for diabetes quality of care indicators in individuals with any mental disorder versus without mental disorders to investigate the association between the presence of a mental disorder and diabetes quality of care indicators, including overall diabetes monitoring and treatment. Studies were excluded if it was not possible to generate pooled quantitative data. The primary outcome was a binary composite measure of diabetes quality of care, meaning the percentage of people receiving any diabetes monitoring and treatment (ie, urine albumin-creatinine ratio test, HbA1c test, blood pressure measured, foot surveillance, serum creatinine test, serum cholesterol test, BMI recorded, smoking status recorded, retinal monitoring). Secondary outcomes were study-specific diabetes quality of care individual indicators matched to the nine NICE diabetes monitoring indicators and specific diabetes interventions and anti-diabetes medications. We analysed primary and secondary outcomes according to any mental disorder and to specific diagnostic subgroups. Study quality was evaluated using the Newcastle-Ottawa Scale (NOS). FINDINGS: Data from 49 studies (42 cohort and seven case-control) were included, comprising 5 503 712 individuals with diabetes, of whom 838 366 (15·2%) had a diagnosed mental disorder (defined using ICD-9 or ICD-10 criteria in 40 studies). Sex was reported in 35 of 49 studies, comprising 4 250 666 individuals, 1 956 506 (46·0%) of whom were female and 2 294 160 (54·0%) were male. The mean age was 61·4 years (SD 8·7; range 47-82 years). 38 studies reported on various mental disorders, 21 on mood disorders spectrum, 21 on major depressive disorder, 20 on schizophrenia, 11 on bipolar disorder, 11 on substance use disorder spectrum, including alcohol use disorder, six on dementia, five on anxiety disorder spectrum, and one on personality disorder spectrum. Most studies were high quality and spanned Asia, North America, Europe, and Australasia. Significant negative associations were observed between having any mental disorder and the likelihood of receiving any recommended diabetes monitoring (29 studies, OR=0·81 [95% CI 0·70-0·94], p=0·0049). Negative associations were also observed for HbA1c measurement (24 studies, 0·81 [0·68-0·97], p=0·024), retinal screening (21 studies, 0·77 [0·63-0·95], p=0·013), lipid and cholesterol measurement (20 studies, 0·83 [0·69-0·99], p=0·043), foot examination (11 studies, 0·85 [0·76-0·95], p=0·0044), and renal investigation (16 studies, 0·78 [0·63-0·96], p=0·022). A significant positive association was found between any mental disorder and recorded smoking status (two studies, 1·09 [1·02-1·17]; p=0·0076). Any mental disorder was significantly associated with higher odds of receiving insulin (ten studies, 1·52 [95% CI 1·16-1·99]; p=0·0022), but negatively associated with treatment with a GLP-1 receptor agonist (two studies, 0·26 [0·13-0·49]; p<0·0001). There was no evidence of publication bias. INTERPRETATION: Mental disorders are negatively associated with receiving adequate diabetes monitoring and GLP-1 agonist therapy. Addressing these disparities has the potential to address the increased mortality associated with mental disorders. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wagner E, Højlund M, Fiedorowicz JG, et al. Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026. PMID: 41506273. doi:10.1016/S2215-0366(25)00332-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。